Back to School: How biopharma can reboot drug development. Access exclusive analysis here

GenKyoTex: Opportunity NOX

Nicotinamide-adenine dinucleotide phosphate oxidases are known to play a role in cardiovascular and neurological diseases, but blocking some isoforms is associated with toxicity, and determining selectivity for specific enzymes has so far not been possible. GenKyoTex S.A. believes it has the only available technology for isoform-selective screening of small molecules that

Read the full 512 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE